A former prime-time news anchor with over two decades of international journalism experience, Isabelle moderates at the highest level of global leadership. From heads of state to Fortune 500 CEOs, she is trusted to shape complex, high-stakes conversations with authority, precision and presence. Combining editorial depth with stage command, she transforms panels into meaningful, memorable dialogue.

Isabelle was the lead anchor for Euronews-NBC and criss-crossed the planet interviewing heads of state and government, CEOs and celebrities generating more than 3 million views on YouTube.

Isabelle has moderated at high-level and large-scale events throughout her career, including the first ever EU Presidential debate, deep dives at the Davos World Economic Forum and the European Commission. Now, this is her principal activity: she works with corporates, international organisations and NGOs around the world on issues relating to all things health, sustainability, tech/AI and more. Today her clients include the European Commission, the UN, WHO, The Consumer Goods Forum, Proctor & Gamble, LEAP and Saatchi & Saatchi. She has been MC for award ceremonies for the UN, EU and chaired closed-door discussions including with former German Chancellor Angela Merkel and European leaders.

Her interviews include presidents and prime ministers from Russia, Iran, Brazil, Argentina, Germany, Italy, Portugal as well as the heads of the UN and the European Commission.  She has spoken to the King of Jordan, the Prince and Princess of Monaco, interviewed Richard Branson, Andrea Bocelli, Mike Tyson and Karl Lagerfeld to name but a few.

Before heading to Euronews, Isabelle worked for CNN, APTN and Reuters.

Isabelle is bilingual in French and English and holds British and German nationality. She is a disability activist, the President of a charity supporting people with autism and does pro-bono work with the charity Lake Aid, which helps unaccompanied minors, asylum seekers and homeless families.

Born in Haiti, Marjorie Michel was elected federal member of Parliament for the electoral district of Papineau, Quebec, in 2025. She was subsequently appointed Minister of Health of Canada.

Passionate about human relations, Minister Michel holds a master’s degree in social, work and organizational psychology from the Catholic University of Louvain (Belgium) and a certificate in diplomatic and strategic studies from the Centre for Diplomatic and Strategic Studies (CEDS).

She began distinguishing herself on the international stage in the 1990s as an advisor to the Haitian Embassy in Paris, before becoming responsible for logistics coordination for the General Assembly of the Organization of American States (OAS) in 1995, for which she received official recognition from the US government.

Beyond her titles, Marjorie Michel is recognized for her work in the field. An active member of the Quebec Business Women’s Network since 2005, she has always advocated for the place of women from diverse backgrounds in decision-making circles.

Her political involvement began in the Viau provincial riding in Montreal, parts of which are part of the Papineau federal riding. She has successfully led numerous election campaigns.

In 2021, she made history when she became the first Black woman to be appointed Deputy to the Chief of Staff to former Prime Minister Justin Trudeau—a historic milestone for diversity in Canadian politics.

Her approach is deeply inclusive: she advocates for a vision of health rooted in social inequalities, mental health, and reconciliation with Indigenous communities.

Michel Demaré is Member of the Board of AstraZeneca since September 2019 and Chair since April 2023. 

He is also Chair of the Nomination and Governance Committee and member of the Remuneration Committee. 

Michel was previously Vice-Chairman of UBS Group AG (2010 to 2019), Chairman of Syngenta and the Syngenta Foundation for Sustainable Agriculture (2013 to 2017) and Chairman of SwissHoldings (2013 to 2015). Between 2005 and 2013, Michel was CFO of ABB Ltd and also acting interim CEO during 2008. He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005. Prior to that, he spent 18 years at The Dow Chemical Company, in several international finance functions, including the CFO of Dow’s Global Polyolefins and Elastomers division between 1997 and 2002. He began his career as a banking officer at Continental Illinois’ Belgian subsidiary. Michel graduated with an MBA from the Katholieke Universiteit Leuven, Belgium, and holds a degree in applied economics from the Université Catholique de Louvain, Belgium. 

Michel is a Non-Executive Director of Vodafone Group Plc and Louis Dreyfus Int’l Holdings BV, Chairman of IMD Business School and Chairman of Nomoko AG. 

Penny Heaton, M.D., is Global Head of the Office of the Chief Medical Officer at Jonson & Johnson. She leads efforts to address global health challenges that focus on Medical Safety; Epidemiology; Bioethics, Policy & Partnerships; and Life Cycle Management in alignment with the company’s Credo.

With more than 20 years of experience in infectious diseases and vaccine development, Penny previously served as Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute (Gates MRI), leading the development of investigational products for tuberculosis, malaria and other diseases. She also worked as Director of Vaccine Development at the Gates Foundation, addressing diseases like HIV, rotavirus and polio.

Penny began her career at The Centers for Disease Control and Prevention where she focused on diarrheal disease surveillance and outbreak investigations, igniting her interest in infectious diseases. She is a graduate of the University of Louisville School of Medicine, board-certified in Pediatrics, and a fellow of the American Academy of Pediatrics.

Dr. Florika Fink Hooijer leads the DG HERA in the European Commission. DG HERA’s primary mission is to counter vulnerabilities and strategic dependencies within the EU in relation to threat analysis, development, production, procurement, stockpiling and distribution of medical countermeasures, irrespective of the cause of the health emergency.

Florika combines strong leadership skills with in-depth experience in EU policy making and international negotiations. A lawyer by training, she holds extensive expertise in foreign and security policy, humanitarian aid and disaster risk reduction, including civil-military cooperation as well as environmental policies.

Michael Lobritz, MD, PhD is Global Head of the Infectious Diseases at F. Hoffmann La-Roche, Ltd (Roche) in Basel, where the Roche team is pursuing the discovery and clinical development of novel antibiotics and antivirals. Founded in 1896 in Basel, Switzerland, Roche has grown into the world’s largest biotechnology company and global leader in in vitro diagnostics. He also serves on committees and boards focused on the challenges of antimicrobial resistance (AMR) and infectious diseases, including the AMR Industry Alliance and AMR Action Fund. Prior to joining Roche in 2017, Michael was attending physician in medicine and infectious diseases at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School, both in Boston, USA. He is a Fellow of the Infectious Diseases Society of America.

David Reddy is Director General of IFPMA, leading the organization’s mission to translate scientific progress into the next generation of medicines and vaccines and championing innovation that delivers a healthier future for people everywhere.

Prior to joining IFPMA, David served for 13 years as CEO of Medicines for Malaria Venture (MMV), where he played a pivotal role as the organization established the largest portfolio of malaria drugs ever assembled, bringing forward 15 medicines that have saved more than 15 million lives.

In 2026, David joined the World Health Summit Council. He has also been a Board Member of the Coalition for Epidemic Preparedness (CEPI) from 2018-2026 and serves on the Board of Malaria No More UK.

Before joining MMV, David was a Vice President at Roche, where he held corporate responsibility for Roche’s response to the 2009/2010 influenza pandemic. In this role, he led the work to develop, communicate, and implement the company’s strategy for working with governments and the WHO on pandemic preparedness, and establishing a sustainable access program. Prior to this, he led Roche’s HIV/AIDS Disease Area Strategy Team, providing strategic leadership for Roche’s HIV portfolio.

David holds a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand and completed a post-doctoral fellowship in molecular neurobiology at the Friedrich-Miescher Institute in Basel, Switzerland. David has more than 30 years of management experience in the healthcare sector, including leadership of drug development teams including working on anti-viral diagnostics, a recombinant vaccine, and novel antiviral strategies; licensing and alliance management; market analytics and business planning; product and disease area management; and interfacing with governments, NGOs, and patient advocacy groups in priority disease areas.